N/A
Manufactured by Advanz Pharma (US) Corp.
5,859 FDA adverse event reports analyzed
Last updated: 2026-04-15
PREDNISOLONE SODIUM PHOSPHATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Advanz Pharma (US) Corp.. The most commonly reported adverse reactions for PREDNISOLONE SODIUM PHOSPHATE include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, TREATMENT FAILURE, CONDITION AGGRAVATED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for PREDNISOLONE SODIUM PHOSPHATE.
Out of 2,318 classified reports for PREDNISOLONE SODIUM PHOSPHATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 5,859 FDA FAERS reports that mention PREDNISOLONE SODIUM PHOSPHATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, OFF LABEL USE, PYREXIA, TREATMENT FAILURE, CONDITION AGGRAVATED, VOMITING. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Advanz Pharma (US) Corp. in connection with PREDNISOLONE SODIUM PHOSPHATE. Always verify the specific product and NDC with your pharmacist.